Search

Displaying results 5511 - 5520 of 10000 in total
  1. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity.

  2. Drug

    Ramoplanin

    go.drugbank.com/drugs/DB04952
    Experimental

    Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.

    Categories: Amino Acids, Peptides, and Proteins
  3. Drug

    Latrunculin B

    go.drugbank.com/drugs/DB08080
    Experimental

    Latrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge _Latrunculia magnifica_.

  4. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) … BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR).

  5. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.

    Categories: ketobemidone and antispasmodics
  6. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. … It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.

  7. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing. … PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes.

  8. Drug

    Metampicillin

    go.drugbank.com/drugs/DB13836
    Experimental

    Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin.

  9. Drug

    MRx-4DP0004

    go.drugbank.com/drugs/DB15751
    Investigational

    It is a live biotherapeutic derived from the microbiota of a healthy human infant.

  10. Drug

    Diosmetin

    go.drugbank.com/drugs/DB11259
    Approved

    Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231]. … Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflamatory activities [A27231]. It also acts as a weak TrkB receptor agonist [A27230].